Clinical trials are currently standing at a pivotal juncture, grappling with challenges in patient enrollment and retention, alongside limited resources at trial sites. In this landscape, the importance of fortified site support, collaboration, and the implementation of patient-centric trial models has come to the forefront.
In a recent discussion with Applied Clinical Trials, Caroline Potts shed light on the necessity of operational flexibility within clinical trials. She emphasized the detrimental impact of rigid standard operating procedures and budget constraints on staff burnout. Potts advocated for strategies like in-home visits and community outreach as pivotal in mitigating recruitment delays and enhancing trial diversity. Moreover, she underscored the financial constraints impeding the adoption of patient-centric models, calling for enhanced dialogue and innovative solutions. Potts stressed the significance of community engagement, the utilization of temporary clinic sites, and collaborative endeavors among key stakeholders to better cater to diverse populations in clinical trials.
The escalating complexity of clinical trial protocols has posed significant challenges to patient recruitment and retention, further exacerbating delays in trial timelines at sites that are already grappling with resource constraints. Simultaneously, there is a growing demand for diversity, decentralization, and real-world data generalizability, prompting a reassessment of the delivery methods and locations of trials.
This article delves into a roadmap designed to assist trials in adhering to timelines, fortifying patient recruitment and retention, and elucidates how alleviating operational pressures and enabling clinical research in novel communities globally can be achieved through the establishment of more accessible and efficient sites.
Industry-wide Challenges & the Impact on Sites
To comprehend how industry-wide challenges compound the existing pressures faced by trial sites, it is imperative to first grasp an overview of these challenges. The statistics underscore the arduous nature of bringing new therapies to the market, emphasizing the high-risk nature of clinical trials. The repercussions of these challenges are most acutely felt at the site level, where the responsibility lies on them to ensure robust patient enrollment, protocol adherence, and data quality while retaining patients throughout the trial.
This burden is magnified by the prevalent under-resourcing and staff shortages at many trial sites due to burnout, exacerbating the challenges they face. While each site may encounter unique hurdles, common barriers include:
Upon closer examination of these challenges, it becomes apparent that the onus rests on the broader industry to reassess its engagement with and support for clinical trial sites. The post-COVID-19 era has rendered clinical trial sites an even more intricate ecosystem, necessitating a shift from the current unsustainable approach towards a more progressive and sustainable model.
Evolving Relationships with Sites
The conventional transactional relationships between research sites and sponsors or CROs may not align with the patient-centric experience sought by participants in trials, often resulting in reduced enrollment and retention rates. Cultivating more relational relationships between sites and sponsors or CROs fosters a deeper understanding and shared values. This can be achieved through:
These modifications may appear simplistic, but they must be implemented with intent and specific outcomes in mind. Understanding the needs of all parties facilitates the focused allocation of resources, time, energy, and funds to areas most likely to drive the desired change.
Breaking Down Barriers for Patients & Sites
Once the requirements of sites are comprehended, the formulation and execution of a strategy aimed at empowering them become feasible. Site-enabled strategies hold the potential to mitigate recruitment delays, enhance trial diversity, and establish an actionable patient-centric approach to clinical trials. The long-term advantages of adopting a more human-centered approach to trials are manifold:
However, developing and implementing strategies that yield such outcomes can be resource-intensive, particularly for singular trials. Consequently, sponsors and CROs are turning towards site networks for solution.
The Role of Site Networks in Transforming Clinical Trials
Site networks serve as enablers for sites to conduct clinical research effectively. While various networks operate with distinct goals, their primary aim is to empower sites to innovate their trial delivery methods, encompassing in-home visits and community-based support, thereby enhancing trial success.
Contrary to the misconception that joining a network entails sacrificing independence or being assimilated into a corporate structure, many networks are designed to enhance site autonomy. They provide access to infrastructure, operational support, and experienced resources that individual sites may lack, ultimately bolstering long-term research capacity and simplifying trial delivery without compromising a site’s unique identity.
Redesigning Trials around People, Not Processes
The success of a clinical trial commences with a thoughtful, inclusive trial design that prioritizes sites and places patients at the forefront from the outset. The challenges faced today, from underperforming sites to escalating dropout rates, are not predetermined outcomes but rather a reflection of a system entrenched in antiquated models.
For a substantial acceleration in drug development, enhanced diversity, and reduced trial failure rates, a paradigm shift in approach is imperative. Listening to site teams, investing in under-resourced communities, and delivering flexible support that fosters success for all participants are pivotal. Site networks can serve as a potent catalyst for this transformative change when rooted in collaboration rather than control, and oriented towards capability over conformity.
In an industry underpinned by innovation, the time has come for the trial infrastructure to evolve in parallel.
Takeaways:
– Cultivating relational relationships between sites and sponsors can enhance trial enrollment and retention rates
– Site-enabled strategies are pivotal in reducing recruitment delays, enhancing trial diversity, and establishing patient-centric trials
– Site networks play a crucial role in empowering sites to conduct clinical research effectively
Tags: clinical trials, regulatory
Read more on appliedclinicaltrialsonline.com